A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Summary

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  AZD0901

  AZD0901 will be administered as an IV infusion.

• Drug
  Rilvegostomig

  Rilvegostomig will be administered as an IV infusion.

• Drug
  Trastuzumab Deruxtecan (T-DXd)

  T-DXd will be administered as an IV infusion.

• Drug
  Capecitabine

  Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.

• Drug
  5-Fluorouracil (5-FU)

  5-FU (Fluoropyrimidine) will be administered as an IV infusion as chemotherapy standard of care.

• Drug
  FLOT Chemotherapy

  FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.

Locations (70)